SCHEMBL1440123

SCHEMBL1440123

COC(=O)c1cnccc1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT3 Q9NTG7 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
KDM4E B2RXH2 6/20 0.61
ALDH1A1 P00352 3/20 0.61
GLA P06280 2/20 0.61
GAA P10253 2/20 0.61
LMNA P02545 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
CYP46A1 Q9Y6A2 1/20 0.49
KMT2A Q03164 1/20 0.45
HSD17B10 Q99714 4/20 0.43
FGFR1 P11362 1/20 0.43
SRC P12931 1/20 0.43
FGFR2 P21802 1/20 0.43
FGFR4 P22455 1/20 0.43
FGFR3 P22607 1/20 0.43
HTT P42858 2/20 0.43
ATM Q13315 2/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30957166 1.00 SIRT3 (0.61) SIRT3TDP1KDM4EALDH1A1GLA
SCHEMBL31291300 0.85 KDM4E (0.66) SIRT3TDP1KDM4EALDH1A1GLA
SCHEMBL9107394 0.85 KDM4E (0.66) SIRT3TDP1KDM4EALDH1A1GLA
SCHEMBL29416299 0.84 KDM4E (0.70) SIRT3TDP1KDM4EALDH1A1GLA
SCHEMBL68952 0.84 KDM4E (0.70) SIRT3TDP1KDM4EALDH1A1GLA
SCHEMBL3964969 0.83 TDP1 (0.65) SIRT3TDP1KDM4EALDH1A1GLA
SCHEMBL4591568 0.83 TDP1 (0.65) SIRT3TDP1KDM4EALDH1A1GLA
SCHEMBL5802324 0.83 TDP1 (0.59) SIRT3TDP1KDM4EALDH1A1GLA
Hydrochloric Acid SCHEMBL18204823 0.83 KDM4E (0.64) SIRT3TDP1KDM4EALDH1A1GLA
SCHEMBL6641437 0.82 ALDH1A1 (0.50) SIRT3TDP1KDM4EALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146040-A1 USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS Madera Therapeutics, LLC (US) 2026-05-28 US disclosed
EP-4688753-A1 KCC2 POTENTIATORS AND USES THEREOF Axonis Therapeutics, Inc. (US) 2026-02-11 EP disclosed
EP-4688754-A1 KCC2 POTENTIATORS AND USES THEREOF Axonis Therapeutics, Inc. (US) 2026-02-11 EP disclosed
US-20260028327-A1 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS, INC. 2026-01-29 US disclosed
US-20260028351-A1 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS, INC. 2026-01-29 US disclosed
EP-4612154-A1 REGULATORS OF PORPHYRIN AND INTERMEDIATES Madera Therapeutics, LLC (US) 2025-09-10 EP disclosed
US-20250230168-A1 AZASPIRO WRN INHIBITORS GILEAD SCIENCES, INC. 2025-07-17 US disclosed
WO-2024211686-A1 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS, INC. (US) 2024-10-10 WO disclosed
WO-2024211744-A1 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS, INC. (US) 2024-10-10 WO disclosed
US-20240262832-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2024-08-08 US disclosed
WO-1994005288-A1 ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM UNIVERSITY OF FLORIDA (US) 1994-03-17 WO disclosed
US-4957640-A Corrosion prevention with compositions prepared from organic fatty amines and nitrogen-containing aromatic heterocyclic compounds THE DOW CHEMICAL COMPANY (US) 1990-09-18 US disclosed
US-4812471-A Hypoglycemic 5-(isoxazolyl or isothiazolyl)-oxazolidine-2,4-diones PFIZER INC. (US) 1989-03-14 US disclosed
US-4765839-A PAVING THE DOW CHEMICAL COMPANY (US) 1988-08-23 US disclosed
US-4761473-A CORROSION RESISTANCE OF OIL OR GAS WELLS THE DOW CHEMICAL COMPANY (US) 1988-08-02 US disclosed
US-4753956-A Hypoglycemic 5-substituted oxazolidine-2,4-diones PFIZER INC. (US) 1988-06-28 US disclosed
US-4689336-A Hypoglycemic 5-substituted oxazolidine 2,4-diones PFIZER INC. (US) 1987-08-25 US disclosed
US-4565820-A ANTIDIABETIC AGENTS PFIZER INC. (US) 1986-01-21 US disclosed
US-4431810-A HYPOGLYCEMIC AGENTS PFIZER INC. (US) 1984-02-14 US disclosed
US-4342771-A Hypoglycemic 5-substituted oxazolidine-2,4-diones PFIZER INC. (US) 1982-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028327-A1 KCC2 POTENTIATORS AND USES THEREOF HCN1, KCNC1, HCN2 SIRT3 1922/4885TDP1 2604/4885KDM4E 3406/4885
US-20250230168-A1 AZASPIRO WRN INHIBITORS WRN, RECQL, BLM SIRT3 1157/4885TDP1 54/4885KDM4E 3650/4885
US-20260028351-A1 KCC2 POTENTIATORS AND USES THEREOF GRIN2C, HCN1, KCNC1 SIRT3 2352/4885TDP1 2638/4885KDM4E 3650/4885
US-20260146040-A1 USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS CTRB1, CTRB2, CPN1 SIRT3 3516/4885TDP1 3079/4885KDM4E 4415/4885
US-20240262832-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF GBA1, GAA, GBA2 SIRT3 1520/4885TDP1 492/4885KDM4E 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.